Industry

Decision underlines a commitment to leveraging advanced safety technology by QGAir as part of a holistic safety program. Brazos Safety Systems is proud to support QGAir in this program. BRISBANE, AUSTRALIA–(BUSINESS WIRE)–#AviationSafety–Queensland Government Air (“QGAir”), the State’s dedicated aviation capability, continues to provide world-leading emergency response and support services to communities across Queensland. Operating as … [Read more…]

FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at the Lotte New York Palace in New York, NY. About Personalis, Inc. At Personalis, we are transforming the active … [Read more…]

The patent, issued to Brainiac’s parent company Ingenuity Brands, spans fruit and vegetable products fortified with omega-3s and choline through February 2040 SAN FRANCISCO–(BUSINESS WIRE)–Brainiac Foods and its parent company, Ingenuity Brands, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering food products nutritionally enhanced with omega-3s and … [Read more…]

Data underscores a deepening culture crisis in healthcare and an opportunity for organizations to rebuild trust, engagement, and balance MIDVALE, Utah–(BUSINESS WIRE)–Only 18% of physicians report being highly engaged in their workplaces, according to new data from CHG Healthcare’s Physician Sentiment Survey. The findings reveal a deepening culture crisis driven by administrative burdens, staffing shortages, … [Read more…]

Peer-reviewed data published in Neurosurgery show that SOLOPASS® 2.0 delivers significantly higher accuracy than free-hand EVD placement. SOLOPASS® 2.0 achieved consistent accuracy across all clinician experience levels. BLUE BELL, Pa.–(BUSINESS WIRE)–inTRAvent Medical Partners LP, a pioneer in bedside, image-guided neurosurgical innovation, today announced the publication of a peer-reviewed study in Neurosurgery evaluating the accuracy of … [Read more…]

Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1 The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2 The new liquid formulation of infliximab, available in … [Read more…]

MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed … [Read more…]

 Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in Europe Omlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence INCHEON, South Korea–(BUSINESS WIRE)–The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s … [Read more…]

Halda Therapeutics acquired by Johnson & Johnson for $3.05 billion – the largest acquisition ever across any therapeutic area for a Phase 1 company Scorpion Therapeutics acquired by Eli Lilly for Up to $2.5 billion – one of the highest-value strategic transactions announced in early 2025 Vigil Neuroscience acquired by Sanofi for a $470 million … [Read more…]

Announces EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate with Rapid, Continuous and Complete (>90%) In Vivo pSTAT6 Suppression and Efficacy Comparable to Dupilumab in Asthma and Atopic Dermatitis Disease Models Announces EDP-978, an Oral, Once-Daily KIT Inhibitor Clinical Candidate with Plans to File an Investigational New Drug Application in Q1 2026 Reported Positive Topline … [Read more…]